Testosterone Review Links Levels to Atrial Fibrillation
Analysis based on 6 articles · First reported Sep 01, 2026 · Last updated Sep 10, 2026
The review is unlikely to move broad markets but could influence sentiment around testosterone replacement therapy products and the pharmaceutical companies that manufacture them, as it raises questions about optimal dosing targets. Any shift toward lower target levels or steady-release formulations could modestly affect prescribing patterns and product mix in the hormone therapy market.
A narrative review published in the Journal of the Pediatric Endocrine Society concludes that the relationship between testosterone levels and atrial fibrillation (AF) appears to follow a U-shaped pattern, with both low and high testosterone associated with higher AF risk and the lowest risk in the middle of the normal range. The review, co-authored by Rajat S. Barua of the United States — Providence Veterans Affairs Medical Center, Anand Reddy Maligireddy of the University of Kansas Medical Center, and Shumedha T. Barua of the Kansas City VA Medical Center, synthesizes population studies, clinical research, and laboratory work reported since 2025. The authors suggest clinicians treating men with testosterone replacement therapy aim for a total testosterone target of roughly 350-550 ng/dL rather than the high end of normal, prefer steady-release formulations for men with elevated cardiovascular or arrhythmic risk, use calculated free testosterone when sex hormone-binding globulin is abnormal, maintain normal hematocrit, and monitor heart rhythm, blood pressure, and kidney and liver function. The review received no external funding and is a narrative summary rather than a meta-analysis, so its conclusions are interpretive and the proposed target range has not been tested prospectively.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard